Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 77

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 77
---
 development (commercial), employee headcount, market capitalization and revenue. Amicus Therapeutics and Horizon Therapeutics, which were members of our 2023 peer group, were not included in the 2024 Peer Group as they no longer met all of the relevant criteria. Based on the approved peer group, Aon prepared an executive compensation assessment that included publicly-available proxy information and certain non-public information for third-party executive compensation for the compensation committee’s consideration. In analyzing and setting our executive compensation program for 2024, the compensation committee compared certain aspects of our named executive officers’ compensation, including base salary, target bonus and long-term equity incentives, to the compensation levels provided by our 2024 Peer Group as part of this assessment. The compensation committee also reviewed data from the Aon Global Life Sciences Survey, which is comprised of seventeen companies with a median market capitalization of $6.2 billion. Base Salaries The compensation committee reviews the base salaries of our named executive officers annually. We also assess salaries at the time of hire, promotion or other change in responsibilities. In establishing and adjusting executive salaries, the compensation committee considers information regarding base salaries paid by companies in our peer group, other data from Aon, individual performance, complexity of the position and tenure of the executive officer and internal comparability considerations. The Board approves our Chief Executive Officer’s base salary after reviewing the compensation committee’s recommendation. Based on the above and the results of the peer group compensation assessment and other data provided by Aon, we determined that base salaries for our named executive officers in 2024 generally reflected market competitive positioning.

<div align='center'>51</div>

The base salary levels as of December 31, 2024 and December 31, 2023 for our named executive officers are summarized in the table below. The compensation committee believes that these adjustments were appropriate in light of our compensation philosophy, recent accomplishments including the broad label expansion for Elevidys, and the need to retain the Company’s executive talent.

| Name                        |     | Title                                         |     | Salary 
 2024   |         |     | Salary 
 2023   |         |     | $      
 Change |        |     | %      
 Change |   |   |
|:----------------------------|:----|:----------------------------------------------|:----|:-------|--------:|:----|:-------|--------:|:----|:-------|-------:|:----|:-------|--:|:--|
| Douglas S. Ingram           |     |